The role of multimodality therapy and surgery for the treatment of locally advanced pancreatic cancer remains to be determined. Although no randomized trials have been done to determine the optimal management of this difficult clinical problem, numerous series reporting successful surgical resection with negative (R0) or microscopic margin (R1) showing favorable long-term survival provide a basis for an aggressive approach in selected cases of advanced cancer of the pancreas. In the absence of conclusive clinical trials, neoadjuvant treatment followed by surgical resection seems to be the optimal approach for locally advanced pancreatic cancers when the potential for surgical resection is suggested by preoperative high quality CT imaging. In particular, when the tumor is within the criteria for borderline resectable pancreatic cancer, efforts to achieve R0 resection are warranted. For those selected cases invading the hepatic artery and superior mesenteric artery, combined arterial resection and reconstruction may be performed to achieve R0 resection. Nonetheless, such a complex procedure should be balanced by a high rate of postoperative complications. In contrast, in cases of tumors invading the celiac axis, R0 resection by combined celiac axis resection can be performed without a high rate of postoperative complications. Survival benefit needs to be verified by further studies in the future. 
INTRODUCTION
To date, the prognosis of pancreas cancer is dismal.
Unfortunately, less than 20% of pancreatic cancer patients are diagnosed at the resectable stage. The resection rate is only approximately 30%, even at a high-volume center.
In contrast, 25-30% of the patients are diagnosed with locally-advanced tumors in the absence of distant metastases at initial presentation. 1 In general, tumors up to T3 stage (AJCC 7 th ed.) are considered to be resectable, but strict criteria to define resectability are still lacking. T4 tumors invading the celiac axis, hepatic artery, and superior mesenteric artery (SMA) are generally considered to be unresectable; however several authors have reported aggressive surgeries such as portal vein, arterial resection, and multivisceral resections in an attempt to increase the curability for the advanced pancreas cancer with favorable results in selected patients. [2] [3] [4] [5] [6] The National Comprehensive
Cancer Network (NCCN) guidelines and consensus statement recently published regarding borderline resectability and unresectability imply that limited involvement of vascular structure by tumor once regarded as a barrier to resection is no longer a contraindication to resection with curative intent. 7 In this article, the recent consensus statement of resectability and the reports of surgical resection for highly selected locally advanced pancreas cancer are reviewed. In addition, we present our survival data according to the curability of resection and 4 cases invading the celiac axis, which were resected by a modified Appleby procedure.
STAGING OF THE LOCALLY ADVANCED PANCREAS CANCER
The seventh edition of AJCC-UICC TNM staging of pancreatic cancer has not changed from that of the sixth edition. Tumors involving the celiac axis and superior mesenteric artery are locally advanced tumors and are defined as T4. These T4 tumors are generally regarded as unresectable, as evident on preoperative CT scan. However, preoperative identification of major arterial invasion is not always accurate as reported by several radiologic studies. [8] [9] [10] Thus, the risk of inadvertent exclusion from potentially curative resection should be considered in the management of patients with locally advanced pancreatic cancer.
With the advances in high quality CT imaging, new concepts to define the extent of venous and arterial invasion have been developed and a subset of tumors called borderline resectable pancreas cancer (BRPC) that blur the distinction between resectable and locally advanced pancreatic cancer is categorized. 11 BRPC, once considered to be unresectable, has now been accepted as a resectable tumor, although it has a high risk of developing into disseminated disease and for incomplete resection to occur.
With neoadjuvant chemoradiotherapy for the BRPC patients, a considerable amount of patients have been reported to undergo complete resection. months; p=0.581). 15 Nevertheless, higher morbidity and mortality rates associated with arterial resection remain to be overcome. showed a higher rate of R0 resection and a favorable 1-year and 5-year survival rates (71% and 42%, respectively). 16 The authors concluded that distal pancreatectomy with celiac axis resection for locally advanced pancreatic body cancer is feasible, safe, and has the potential to achieve complete local control. On CT imaging, invasion to the celiac artery and splenic artery was evident in all cases. Distal pancreatectomy with celiac resection was performed with subtotal gastrectomy in one case and with preservation of the stomach in the remaining 3 cases. R0 resection was possible in 3 cases, except for in 1 case which had a positive para-aortic lymph node invading left renal vein. Three patients with R0 resection are free from tumor recurrence for 14, 4, and 3 months, respectively. These patients should be followed up longer to determine the effect on survival. The patient with R1 resection had liver metastasis at 12 months after surgery and is alive 15 months after surgery.
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